ReSPOnD (Retrospective Study of Patient Outcomes Following ARCADIAN)

  • Research type

    Research Study

  • Full title

    A retrospective analysis of outcome data of patients following the ARCADIAN (Atovaquone with Radical ChemorADIotherapy in locally Advanced NSCLC) trial.

  • IRAS ID

    335371

  • Contact name

    Geoff Higgins

  • Contact email

    geoffrey.higgins@oncology.ox.ac.uk

  • Sponsor organisation

    University of Oxford

  • Clinicaltrials.gov Identifier

    266541, ARCADIAN reference number

  • Duration of Study in the UK

    1 years, 0 months, 1 days

  • Research summary

    This work will retrospectively analyse patient data from the ARCADIAN trial. This will involve using NHS England and NHS Scotland to access patient data via the National Cancer Registration Dataset and Hospital Episode Statistics. This will allow us to access data including patient mortality at 6 months and 12 months after the post-treatment 6 month follow up and tumour recurrence, new cancer diagnoses, additional non-cancer diagnoses post-treatment completion and participant hospitalisation after the post-treatment 6 month follow up. This will provide further understanding of the effects of atovaquone given alongside a chemoradiotherapy treatment regimen for non-small cell lung cancer that has spread locally and has a hypoxic (low oxygen) environment.

  • REC name

    HSC REC A

  • REC reference

    24/NI/0054

  • Date of REC Opinion

    16 Apr 2024

  • REC opinion

    Favourable Opinion